Could a dementia drug shield kids' brains from radiation damage?
NCT ID NCT03194906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether memantine, a drug used for dementia in adults, could help prevent memory and thinking problems in children receiving brain radiation for tumors like glioma or craniopharyngioma. 41 children aged 6-21 took either memantine or a placebo during radiation. The goal was to see if the study was feasible and if memantine could protect cognitive function. Results are still being analyzed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Memantine (a drug used for dementia in adults)
- What this could lead to
- If it works, this could point toward a way to reduce thinking and memory problems in children after brain radiation.
- What could go wrong
- This is a very early pilot study with only 41 children, so results may not be conclusive. Memantine is not yet approved for children, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRANIOPHARYNGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Could a parasite drug fight childhood brain tumors?
- A new PET scan tracks brain tumors by their appetite for tryptophan
- Can a simple dye help surgeons see brain tumors in real time?
- New platform trial takes on NF2 tumors with multiple drug strategies